A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March 2013 issue of Nature by Prof Dimmler, Boon, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Myocardial Infarction: Deubiquitylase HAUSP improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10). This study suggests, for the first time, that HAUSP, by increasing the expression of PNUTS/PPP1R10, it may: (1) inhibit DNA damage responses, (2) inhibit telomere shortening; and (3) promote cardimyocyte survival. Therefore, by consuming activators of HAUSP, one may protect himself/herself from ageing-associated decline in cardiac function. Together, pharmacological formulations encompassing “HAUSP activators” may be used to improve cardiac function after myocardial infarction.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for Myocardial Infarction: Deubiquitylase HAUSP improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 24/February/2015, 22.16, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Amount: $500*
Undisclosed information: How HAUSP increases the expression of PNUTS/PPP1R10